
Cassel Salpeter & Co.’s Q3 healthcare update points to disrupted NIH grant processing, FDA attrition, and tariffs as pressures on drug development and early-stage financing.
Mid-Atlantic based Contract Research Organization (CRO), to provide the company with eClinical solutions for an upcoming Phase III trial.
The trial will be investigating the use of a medical device for wound healing. The study will be conducted at over 30 sites and will recruit up to 300 patients over the course of two years.
Amarex also joins OmniComm’s CRO Preferred Program, which will allow them to offer OmniComm’s electronic data capture solution, TrialMaster, to their clients.






